- Reduced price

Order to parcel locker
easy pay
Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details
Pay with a quick bank transfer, payment card or cash on delivery. Click for more details
If you are a consumer, you can return the goods within 14 days. Click for more details
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates todays available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Data sheet
1. The HER2 alteration in breast cancer
2. HER2 testing in the era of changing guidelines
Advanced Disease
3. Optimal first-line treatment of HER2+ advanced disease
4. Second line therapy and beyond
5. HER2+ CNS metastases
Therapeutics
6. Neoadjuvant therapy
7. Adjuvant therapy
8. Outcomes based on HR status in early stage disease
9. De-escalation of therapy for small tumor
Toxicity considerations
10. Cardiac toxicity of HER2-targeted regimens
11. Non-cardiac toxicity of HER2-targeted therapy
Therapies on the horizon
12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)
13. Harnessing the immune system in HER2+ disease
14. Biosimilars